Your browser doesn't support javascript.
loading
A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens.
Hu, Zhuting; Anandappa, Annabelle J; Sun, Jing; Kim, Jintaek; Leet, Donna E; Bozym, David J; Chen, Christina; Williams, Louise; Shukla, Sachet A; Zhang, Wandi; Tabbaa, Diana; Steelman, Scott; Olive, Oriol; Livak, Kenneth J; Kishi, Hiroyuki; Muraguchi, Atsushi; Guleria, Indira; Stevens, Jonathan; Lane, William J; Burkhardt, Ute E; Fritsch, Edward F; Neuberg, Donna; Ott, Patrick A; Keskin, Derin B; Hacohen, Nir; Wu, Catherine J.
Afiliação
  • Hu Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Anandappa AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Sun J; Harvard Medical School, Boston, MA.
  • Kim J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Leet DE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Bozym DJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Chen C; Harvard Medical School, Boston, MA.
  • Williams L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Shukla SA; Harvard Medical School, Boston, MA.
  • Zhang W; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Tabbaa D; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Steelman S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Olive O; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Livak KJ; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA.
  • Kishi H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Muraguchi A; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Guleria I; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Stevens J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Lane WJ; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA.
  • Burkhardt UE; Department of Immunology, University of Toyama, Toyama, Japan.
  • Fritsch EF; Department of Immunology, University of Toyama, Toyama, Japan.
  • Neuberg D; Department of Pathology, Brigham and Women's Hospital, Boston, MA.
  • Ott PA; Department of Pathology, Brigham and Women's Hospital, Boston, MA.
  • Keskin DB; Harvard Medical School, Boston, MA.
  • Hacohen N; Department of Pathology, Brigham and Women's Hospital, Boston, MA.
  • Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Blood ; 132(18): 1911-1921, 2018 11 01.
Article em En | MEDLINE | ID: mdl-30150207
ABSTRACT
Recent studies have highlighted the promise of targeting tumor neoantigens to generate potent antitumor immune responses and provide strong motivation for improving our understanding of antigen-T-cell receptor (TCR) interactions. Advances in single-cell sequencing technologies have opened the door for detailed investigation of the TCR repertoire, providing paired information from TCRα and TCRß, which together determine specificity. However, a need remains for efficient methods to assess the specificity of discovered TCRs. We developed a streamlined approach for matching TCR sequences with cognate antigen through on-demand cloning and expression of TCRs and screening against candidate antigens. Here, we first demonstrate the system's capacity to identify viral-antigen-specific TCRs and compare the functional avidity of TCRs specific for a given antigen target. We then apply this system to identify neoantigen-specific TCR sequences from patients with melanoma treated with personalized neoantigen vaccines and characterize functional avidity of neoantigen-specific TCRs. Furthermore, we use a neoantigen-prediction pipeline to show that an insertion-deletion mutation in a putative chronic lymphocytic leukemia (CLL) driver gives rise to an immunogenic neoantigen mut-MGA, and use this approach to identify the mut-MGA-specific TCR sequence. This approach provides a means to identify and express TCRs, and then rapidly assess antigen specificity and functional avidity of a reconstructed TCR, which can be applied for monitoring antigen-specific T-cell responses, and potentially for guiding the design of effective T-cell-based immunotherapies.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Especificidade do Receptor de Antígeno de Linfócitos T / Antígenos de Neoplasias Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Especificidade do Receptor de Antígeno de Linfócitos T / Antígenos de Neoplasias Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article